Immuron Company Presentation - May 2016
Released
Released
Announcement PDF
COMPANY PRESENTATION
May 2016
Forward-Looking Statement
Certain statements made in this presentation are forward-looking statements and are based on
Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to
identify forward-looking statements.
Although Immuron believes the forward-looking statements are based on reasonable assumptions,
they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control,
including those risks or uncertainties inherent in the process of both developing and commercializing
technology. As a result, actual results could materially differ from those expressed or forecasted in
the forward-looking statements.
The forward-looking statements made in this presentation relate only to events as of the date on
which the statements are made. Immuron will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect events, circumstances or
unanticipated events occurring after the date of this presentation except as required by law or by any
appropriate regulatory authority.
2
Immuron Limited
Introduction
• Clinical stage biopharmaceutical company focused on oral immunotherapies for
the treatment of inflammatory and gut mediated diseases
• Strong platform technology (dairy-derived antibodies); wide applicability/low cost
- Validations: Product approved and launched; US NIH fully funding Phase II studies (ASH)
• Lead asset IMM-124E targeting fatty liver diseases (NASH / ASH)
- Targeting LPS endotoxins, a key disease mediator, and up-regulation of suppressor T-Cells
- Early studies have shown evidence of anti-inflammatory effects + prevention of fibrosis
- Potential exist to expand the use of IMM-124E in other indications such as diabetes
• NASH represents a blockbuster opportunity. Large and growing market ($35B-$40B
by 2030) driven by obesity epidemic. No approved drugs. High BD activity
• Second key asset is IMM-529 which is targeting C-Difficile. This is a bacterial
infection for which Immuron could get orphan drug designation from the FDA
• Generating growing revenues from OTC products (FY2015: $1.1M)
• Experienced management team and strong support from KOLs
3
Platform Overview
Oral Immunotherapy - A Disruptive Technology
1
2
Vaccines Are
Developed
Antibodies Are
Harvested from
Colostrum
3
Broad Therapeutic Effect
Induction
of
regulatory
T-cells
+
Disease
Specific
Antibodies
+
Bovine
adjuvants
IgG (IgG1)
Clearance of
Targeted
Pathogens
- Reduces systemic
inflammation
- Lowers organ injury
- Not associated with general
immune suppression
- No risks of severe infection
or malignancy
- Easily tolerated by patients
1
An approach to treat inflammatory, infectious and autoimmune diseases through the oral
delivery of antibodies and adjuvants
2
An active process that uses the inherent ability of the GI tract's immune system to control
unwanted systemic immune responses, by inducing systemic regulatory T cells to suppress
inflammation
4
Pipeline
Clinical Assets Targeting Blockbuster Indications
Protectyn
5
Immuron Limited
Travelan/OTC Provide Unique Downside Protection
Travelan Forecast (AU$)
$35,000,000
Other Launches
(eg. Japan)
$30,000,000
EU Full Year
Launch
$25,000,000
$20,000,000
$15,000,000
$10,000,000
$5,000,000
$30.0M
USA, China Full Year
EU Launch
$13.9M
USA Launch
(Late 2016)
$8.1M
$4.6M
$1.1M
$1.8M
$FY2015A
Additional Growth
Opportunities
FY2016E
FY2017E
Geographies: EU,
Japan and Russia
+
FY2018E
FY2019
Potential Rx
Extensions
Peak
+
Product Line
Extensions
6
Key Milestones
Near Term and Long Term Milestones
7
Stellar KOL Support
Principal Investigators & Scientific Advisory Board
Dr Arun Sanyal (MD) – University of Virginia. Professor of Medicine and Former Chairman of the Division of
Gastroenterology, Hepatology and Nutrition, VCU Medical Center. Dr Sanyal is an internationally renowned expert in liver
diseases. He is a former President of the AASLD (American Association for the Study of Liver Diseases) and is the current
Chair of the Liver Study Section at the NIH.
Dr Stephen Harrison (MD) – Professor of Medicine, Uniformed Services University of the Health Sciences, Bethesda,
Maryland; Physician, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas. Chief of Residents, Internal
Medicine, Brooke US Army Medical Center. Dr. Harrison is an internationally renowned expert in NASH and his group has
published seminal work on many aspects in the field. Dr Harrison is the Principal Investigator of Galectin’s GR-MD-02’s Phase
II trial and hold's key roles in other leading clinical NASH studies.
Dr Manal Abdelmalek (MD) – Duke University Medical Center. Dr Abdelmalek is Associate Professor of Medicine at
Duke Medical University Medical Center, Division of Gastroenterology & Hepatology, Section of Hepatobiliary Diseases & Liver
Transplantation. Dr Abdelmalek is a leading investigator in the field of NASH.
Dr Gerhard Rogler (MD, PhD) – Zurich University. Dr Rogler is the Chairman of the Scientific Advisory Board of the
University of Zurich and Professor of Gastroenterology and Hepatology and Consultant Gastroenterologist at the Division of
Gastroenterology & Hepatology, Department of Medicine, Zürich University Hospital, Switzerland. Prof. Rogler is a leader in
the field of Colitis and has authored approximately 200 original peer-reviewed articles.
Dr Miriam Vos (MD) – Emory University. Dr Vos is an associate professor of pediatrics at the Emory University School of
Medicine, and an attending Hepatologist at Children’s Healthcare of Atlanta. She specializes in the treatment of
gastrointestinal disease in children as well as fatty liver disease and obesity. Dr. Vos is also the author of The No-Diet Obesity
Solution for Kids.
Dr. Dena Lyras (PhD) – Monash University. Dr Lyras is associate professor at Monash University, is one of the world’s
leading expert in C-Dfficile. Dr Lyras has spent her research career developing world-leading knowledge of C-Difficile. She
was the lead author of a seminal study published in Nature in 2009, which shed new light on the essential role specific toxins
8
play in causing disease, a discovery that disproved prevailing opinion.
Financials
Financial Position
Financials Overview
•
•
Ticker: ASX (Australia): IMC
Share price (27/05/16): $0.33
Share Price Performance (Mar 15- May 16)
NASH
Recruitment
Update
0.60
C-Difficile
Results
0.55
CVS
0.50
•
Shares outstanding: 75M
•
Market Cap: $27M
•
Cash (as of 31/12/15): $1.0M
0.45
Travelan
US Launch
0.40
0.35
0.30
•
Major Shareholders:
-
Grandlodge ~9%
Authentics Aus. ~6.5%
Chimaera Capital ~4%
Peter Anastasiou ~4%
Retzos Group ~$4%
0.25
0.20
0.15
Immuron Limited (ASX:IMC) - Volume
Immuron Limited (ASX:IMC) - Share Pricing
9
Experienced Management Team
From Leading Organizations
Thomas Liquard
Chief Executive
Officer
Mr Liquard spent the majority of his career at Pfizer in New York in
various commercial positions and was also COO, then CEO, of
Alchemia Limited, an oncology ASX biotech company
Dan Peres, MD
Head of Medical &
NASH
Dr Peres, a surgeon by training, has deep experience in liver diseases
and clinical development having worked for leading Medical Devices
and Pharma companies since 2008
Jerry Kanellos, PhD
COO & Scientific
Officer
Dr Kanellos has over 20 years of experience in the pharmaceutical and
biotech industries including CMC, operations and BD. He has held
senior roles at CSL and Transbio Limited
Dr. Yaron Ilan
Medical and
Scientific Advisor
Dr Ilan is Director-Inpatient Medicine Department at Hadassah Medical
Center. A renowned KOL in NASH and metabolic diseases, he holds
more than 50 patents and authored/co-authored more than 240 articles
Reza Moussakhani
Manufacturing
Quality Director
Mr Moussakhani has extensive experience in implementation of project
/ quality and process improvements, including with Hospira and Sigma
Pharmaceuticals
10
NASH
Metabolic Syndrome
Growing Modern Diseases
Obesity / Unhealthy Living…
… Drives Metabolic Diseases
• Metabolic syndrome is associated with the risk of developing cardiovascular disease, diabetes
and fatty liver
• Some studies have shown the prevalence in the USA to be an estimated 34% of the adult
population; Prevalence increases with age
• No end in sight to the epidemic: e.g.: 350 – 550 million people expected to be diabetic by 2030
12
NASH (Non-Alcoholic Fatty Liver)
Massive Unmet Need – No Treatment approved
NASH: The most severe form of liver injury in the spectrum of nonalcoholic fatty liver disease (NAFLD)
Market
Size
Estimated to top $35B-$40B WW by 2030 driven by
obesity epidemic (Deutche Bank – 2014)
•
Fatty liver: One of most common liver diseases in the industrialized world
•
1 in 5 NASH patients develop liver Cirrhosis
•
1 in 10 will die from NASH
•
Caused by chronic inflammation (local and systemic), associated with
Obesity, Type II Diabetes (insulin resistance) and hyperlipidemia
•
No treatment (approved or in pipeline) addresses organ and systemic
inflammation which repeatedly injures the liver
•
Room exists for new therapies; Treatments in the pipeline have limitations
either with safety or efficacy and likely to be limited in their use
13
NASH Pathophysiology
Overview
NASH – Pathophysiology
Key Takeaways
• Blood derived
antigens determines
tolerance vs.
inflammation
• Kupffer cells play a
key role in liver
inflammation and
fibrosis
• Tregs hold a key role
in tolerance
(homeostasis)
Source: Adapted from Cohen-Naftaly; Scott L. Friedman, 2011.
• Much like hepatic
tolerance the gut
immune system can
promote antiinflammatory effect
14
Liver Homeostasis
Overview
Immunological Mechanisms
• Liver Homeostasis is maintained by both the Innate and adaptive systems
• Circulating LPS and other antigens serve to create tolerance
• All liver cells are exposed to the signals coming from the Gut
• The adaptive system can tailor the immune response using Tregs, phagocytes and
other lymphocytes to create an anti-inflammatory shift.
Source: Haymann et al; Nature Reviews (Feb 2016)
15
IMM-124E
NASH – Mechanism of Action Addresses Unmet Need
IMM-124E
LIVER:
• Activated Kupffer
Cells ↓ (F4/80
macrophages)
• Fibrosis and
Inflammation ↓
GUT:
• Intestinal LPS ↓
• Intestinal Permeability ↓
SERUM:
• Microbiome antigen
change
• Insulin resistance ↓
• Tolerance – Activation
of Innate system to
suppress inflammation
(NKT, DC, macrophages)
• TGF-β ↑
• Circulating LPS ↓
• TNF-α ↓
• IL-2, IL-6, IL-10, IL-12
• Treg ↑ (CD4, CD25,
FoxP3)
16
IMM-124E in Ob/Ob Model
Synergistic Potency
Anti-LPS and Adjuvants in IMM-124E
A Synergistic Effect in Animal Models of NASH
Decreased Liver
Enzymes
Decreased Serum
Triglycerides
900
800
700
*
600
ALT levels (u/L)
500
400
300
200
100
0
Results
• Both Ig and
Adjuvants
demonstrated
potential in
lowering
Triglycerides and
liver enzymes in the
Ob/Ob Leptin
deficient mice
model
* P<0.05; ** P<0.009
An adjuvant effect through the gut
Adar T. Clin Exp Immunol., 2012
• The unique IMM124E composition
demonstrated a
synergistic effect
17
IMM-124E
Animal Models: Macroscopy – Prevents Fibrosis
Fibrotic Liver
IMM-124E Liver
CCl4 (carbon tetrachloride)
CCl4 (carbon tetrachloride)
IMM124E
Treatment with IMM-124E prevents Fibrosis and Inflammation
Mizrahi M. 2013, AASLD; Hepatology 751A
18
IMM-124E
Animal Models: Improves Inflammation and Fibrosis Markers
Group A:
Control
Group C:
Treated
Group B: Naïve
anti LPS
Group A:
Control
Group B:
Naïve anti LPS
Group D:
Treated
Group C:
Treated
Group D:
Treated
Improved Metavir Fibrosis Score
Decrease Portal Inflammation
4
3
*p<0.02
^^ p<0.01
2.4
2.5
*p<0.0009
^^ p<0.0003
3.4
3.5
3
2
2.5
1.4
1.33
1.5
1.8
2
0.66
1
1.5
1
1
0.5
0.5
0
A
B
C
D
Mizrahi M. 2013,
AASLD;
Hepatology 751A
0
0
A
B
C
D
19
IMM-124E
Suppression of F4/80High Macrophages
20
IMM-124E
Phase I/IIa: Improves Liver Function and Insulin Resistance
Results of a Phase I/IIA clinical trial; N=10
30 Days Treatment Endpoint Met; NO SAFETY ISSUES REPORTED
Improved Liver Enzymes
Mizrahi M, J Inflamm Res. 2012;5:141-50
Improved HBA1C, OGTT and HOMA
21
IMM-124E
Phase I/IIa: Improves Inflammatory Biomarkers
Increased
CD4+CD25+FOXP3+ TREGS
Increased GLP1 and Adiponectin
Day 1
Day 30
Mizrahi M. J Inflamm Res. 2012
22
NASH Phase II
Design
Lead Principal Investigator: Arun Sanyal; Former President of the AASLD (American
Association for the Study of Liver Diseases) and current Chair of the Liver Study Section at
the NIH (National Institute of Health)
Scope: Multi-Center, Developed Countries, Double-Blinded, Placebo controlled trial
Sites: 25 sites running in US, Australia and Israel; 1 more to be added in 1H2016
Recruiting 120 patients with biopsy proven NASH; 44 patients already randomized; 18
patients have completed treatment
3 Arms: Placebo, High Dose and Low Dose
Primary Endpoints: Changes in Liver Fat Content confirmed by MRI; Changes in ALT (liver
enzymes)
Secondary Endpoints / Outcome Measures: E.g., Changes in BMI, Changes in
Inflammatory Cytokines and other markers; Changes in Serum/Fecal Concentrations of
Lipopolysaccharide (LPS); Changes in Regulatory T cells in Peripheral Blood Mononuclear;
Changes in Gut Microbiome from Fecal Samples
Timing: Top Line Results (TLR) by Mid-2017
23
NASH – Competitive Landscape
IMM-124E Is Strongly Differentiated
Competition
Bile Acid
Shire - LUM-002
Intercept - Obeticholic acid, modified bile acid
Galmed - Aramchol, Conjugate of Fatty acid and Fatty
bile acid
Anti-fibrotic
Gilead - Simtuzumab, anti-fibrotic
Galectin - galectin proteins
Anti-Inflammatory + (anti-inflammatory, antidiabetic, cholesterol control, FFA)
Immuron – Oral enriched with Anti-LPS Abs
IMM-124E
Strong Differentiation
• Represents a mufti-factorial
approach to NASH, not just one
pathway
• Potentially superior safety profile
- No safety issues as reported by
competitors (e.g., Intercept with
LDL)
• No significant safety concerns that
would limit chronic / long term use
• Can be used across the spectrum
of NASH / NAFLD
Tobira - CCR2 / CCR5 inhibitor
• Can be used in combination with
other agents
Genfit - Peroxisome proliferator
activated receptor alpha
• Oral vs. IV/SubQ
24
NASH – Competitive Landscape
IMM-124E MOA Confers Unique Competitive Profile
IMM124E
• Safety profile potentially opens all segments (Fibrosis – F0-F4 and NAFLD)
• Can potentially be used in combination with other agents, not only as monotherapy
Liver
Cancer
39K
US incidence
Galectin
Conatus
Cirrhosis
off label use potential
NASH
Intercept: Recruiting F1 - F3
Genfit: Recruiting F1 - F3
Galmed: TBD
Tobira: TBD
Payor pushback for use in F0/F1
X
NAFLD
Likely limited offlabel use
0.63% of US Adults:
600K patients
Combo-therapy
potential
IMM-529
2-3% of US adults: 5-7M patients
F0 – F3; Mono
or Combo
Therapy
19% of US Adults: 45M patients
The prevalence of NAFLD is 80-90% in obese adults, 30-50% in patients
with diabetes and up to 90% in patients with hyperlipidemia
Monotherapy
Potential
25
C-DIFFICILE
C-DIFFICILE
A Growing Public Health Issue
Market
Opportunity
• Therapeutic market is expected to grow from US$356.3 million in
2014 to over $1.5 billion by 2024 – CAGR 15%
• Nearly 30,000 patients die each year from c. difficile infections (US)
• Orphan disease (7 years market exclusivity and premium pricing)
• Vancomycin and metronidazole are the current standard of care,
accounting for 80% of patient share (US)
Unmet Need
• However, therapies are plagued by significant CDI recurrences (1st
relapse: 25%; 2nd: 40%; 3rd: 50%) underscoring need for new treatments
• There is also growing resistance to vancomycin treatment
• Highly differentiated
IMM-529
Positioning
• Only asset that targets not only Toxin B but also the spores and
the vegetative cells responsible for recurrence
• Can be used in combination with standard of care
Sources: GlobalData, Decision Resources, CDC
27
IMM-529
Unique MOA in CDI
Spores – Infectious Particles
IMM-529 antibodies bind to
surface antigens on spores
& prevent adheres to host
cells & limit germination.
Heat, ethanol & UV
resistant. Survive gastric
acid, adhere to cells in the
colon & germinate
Vegetative Cells
IMM-529 antibodies bind
to SLP on vegetative cells
& limit colonization.
Fimbriae & other surface
layer proteins (SLP)
contribute to bacterial
colonization. Fimbriae are
used to adhere to other
bacteria & to host cells
and isone of the primary
mechanisms of virulence
Toxin B
IMM-529 antibodies
neutralise toxin B, inhibiting
toxin mediated epithelial
cell apoptosis & limit toxin
translocation into the
systemic circulation &
inflammatory cascades
Toxin B is essential for
virulence. Toxin B disrupt
the cytoskeleton and tight
junctions of intestinal
epithelial cells
28
IMM-529
Results of Pre-Clinical Study
S u r v iv a l
U n in f e c t e d , N o t r e a t m e n t
P e r c e n t s u r v iv a l
Prevention
Studies
100
In f e c t e d , N o t r e a t m e n t
80
In fe c t e d , N o n - im m u n e Ig G t r e a t m e n t
60
In f e c t e d , IM M - 5 2 9 t r e a t m e n t
In f e c te d , V a n c o m y c in tr e a tm e n t
40
20
Demonstrated 80%
efficacy without use
of antibiotics
All studies
statistically
significant
0
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
3 .5
4 .0
h o u r s p o s t in f e c t io n
S u r v iv a l
U n in f e c t e d , N o t r e a t m e n t
In f e c t e d , N o t r e a t m e n t
P e r c e n t s u r v iv a l
Treatment
Studies
100
80
In fe c t e d , N o n - im m u n e Ig G t r e a t m e n t
In f e c t e d , IM M - 5 2 9 t r e a t m e n t
60
In f e c te d , V a n c o m y c in tr e a tm e n t
40
20
Demonstrated 80%
efficacy without use
of antibiotics
0
0
1
2
3
4
(1) Prophylaxis
S u r v iv a l
110
In f e c t e d + S O C
100
P e r c e n t s u r v iv a l
Relapse Studies
D a y s p o s t in f e c tio n
Potentially only
therapeutic
(approved or in
development) that
can treat all phases
of the disease:
90
**
80
p= 0 .0 0 27
In f e c t e d + S O C + IM M - 5 2 9
70
60
50
40
30
20
10
Demonstrated ~90%
survival rate vs. 22%
survival rate in control
group
(2) Treatment
(3) Recurrence
0
0
2
4
6
8
10
12
14
16
18
20
D a y s a f te r v a n c o m y c in tr e a t m e n t c e a s e d
29
IMM-529
Phase 1/2 – Adaptive Trial Design Overview
Phase I/II
A Phase I/II dose escalation & safety assessment in combination with
SOC in C. difficile patients (18 patients x 3 doses; 6 patients per
dose)
- Three escalating dose levels in combination with SOC
- 8 week assessment per patient post SOC treatment
- 6 patients per cohort
Trial Initiation: 2H2016
Results: Expected by Mid-2017
If positive
Phase IIA /
IIB
A Phase IIA (30 patients) and then a IIB (60 patients) Adaptive
Design, Randomized, Double-Blinded, Placebo-Controlled, Study to
evaluate the safety, tolerability and effectiveness of IMM-529 in
combination with SOC in patients with C. difficile infection.
Trial Initiation: 2H2017
30
OTC BUSINESS
Travelan®
A Unique Preventative Product
The only therapy that
prevents Travelers’
Diarrhea by up to
90%
• Marketed in the US,
Australia by Immuron
and by Paladin/Endo in
Canada
• Global market estimate:
US$ 600M - 1.2B
• All-natural product;
Without Travelan®:
Bacteria attach to gut wall
and infect
With Travelan®: Bacteria
neutralized by Travelan®
antibodies
• Clinically proven
• SAFE
• OTC
• Strong brand loyalty
• Multiple life-cycle
opportunities
32
Travelan – Powerful Anti-Infective
Clinical Evidence
• Significantly reduces adherence of CFA/I producing ETEC strains
to a cell-line that mimics the human small intestinal epithelium
PreClinical
Studies
• Significantly reduces the motility of ETEC strains through soft agar
• Binds to both the bacterial surface and flagella
• Has substantially greater reactivity against purified ETEC flagella
antigen than IgG purified from non-immune colostrum powder
• Travelan has undergone clinical testing in patient randomised,
double-blind, placebo-controlled clinical trials (90 patients)
Clinical
Studies
• Results: Travelan confers protection of nearly 91% against
infection of the major strain of E.coli that causes TD
• In addition these trials showed a significant reduction in abdominal
cramps and stomach pain compared to those who did not receive
Travelan. There were no reported treatment-related side effects
33
Travelan Offers Wide Protection
Not Just E-Coli; Travelan Binds to Other Gram-Negative Bacteria
Formulated with 13 Strains of
E-Coli
Proven to Be Cross-Reactive (binds) to Other E-Coli
Strains and Gram-Negative Bacteria
Serotype
ETEC O6: H16
ETEC O8: H19
ETEC O15: H4
ETEC O25: H42
ETEC O27: HR
ETEC O63: HETEC O78: H11
ETEC O114: H21
ETEC O115: HETEC O128: H21
ETEC O148: H28
ETEC O153: H12
ETEC O159: H-
• ETEC strain M452C1 [serotype O20:H-]
• ETEC strain T0225-C4 [O75:H4]
• ETEC strain 83-552 [O126:H-]
• ETEC strain G33 [O126:H12]
• ETEC strain M145C2 [O128:H(NT)]
• ETEC strain E23477/0/A [O139:H25]
• ETEC strain ND782 [O141:H4]
• ETEC strain ND748 [O149:H10]
• ETEC strain E11881A [O25:H42]
• Enterobacter aerogenes strain ATCC 13048
• Enteropathogenic Escherichia coli strain E2348/69
• Klebsiella pneumoniae strain ATCC 26
• Pseudomonas aeruginosa strain ATCC 27853
• Salmonella typhimurium strain ATCC 14028
• Vibrio cholerae strain 6239
• Yersinia enterocolitica strain 67R
• Citrobacter rodentium strain DSB100
• Shigella flexnerii LPS 2a (CVD Lot # 2457T)
• Shigella sonnei LPS 53G (CVD Lot # 95-WRAIR),
• Shigella dysenterii LPS (CVD #1251),
• Salmonella enterica Serovar Typhi LPS (Difco # 3946-25),
• Salmonella enterica Serovar Typhimurium LPS (Sigma # L6511)
• Salmonella enterica Serovar Enteriditis LPS (Sigma # L2012)
Strains #
B2C
C55 3/3c3
PE 595
E11881A
C1067-77
PE 673
H10407
E20738/0
PE 724
EI 37-2
B7A
E8772/0
PE 768
34
Immuron Limited
Travelan/OTC Provide Unique Downside Protection
Travelan Forecast (AU$)
$35,000,000
Other Launches
(eg. Japan)
$30,000,000
EU Full Year
Launch
$25,000,000
$20,000,000
$15,000,000
$10,000,000
$5,000,000
$30.0M
USA, China Full Year
EU Launch
$13.9M
USA Launch
(Late 2016)
$8.1M
$4.6M
$1.1M
$1.8M
$FY2015A
Additional Growth
Opportunities
FY2016E
FY2017E
Geographies: EU,
Japan and Russia
+
FY2018E
FY2019
Potential Rx
Extensions
Peak
+
Product Line
Extensions
35
Travelan / OTC Business
Multiple Paths for Growth
• Travelan/OTC: Unique value proposition that is valued by consumers and
customers
-
High Efficacy
-
High safety profile
-
Only preventative product for Travellers' Diarrhoea
• Multiple ways to keep growing OTC business:
-
Continued penetration of current markets
-
Geographic expansions
-
New products / New formulations (e.g., Shigella)
• Strong Forecast for Growth:
-
AUS: Growing 15% in FY2016 compared to FY2015
-
US: Nearly $1M in guaranteed annual contracts through end of 2016;
Signed 5 distribution agreements in 2015;
-
WW: Pursuing news geographies
-
WW: $1.8M+ in 2016E; $3-$5M in 2017E
36
OUTLOOK & VALUE
Attractive NASH Deal Landscape
Big Pharma Deals Driving Valuations
• (2016) Acquired Nimbus Phase I ACC inhibitor for $400m
upfront + potential for future payments (total deal up to $800M)
• (2010) Acquired Arresto for $225m + potential for future
payments: Phase I asset (LoxL2 antibody) targeting NASH, IPF
• (2015) Phenex: Acquired NASH asset with Phase II running.
Total deal value $470m. Undisclosed upfront, development
and commercial milestones. No royalties
• (2012) Regulus: Preclinical deal. AZN paid $125m per
compound including development and commercial
milestones.
• (2014) Acquired Lumena for $260m. Company had two
Phase II assets for NASH and cholestatic liver disease.
• (2015) Pharmaxis: Acquired NASH asset with Phase I running.
Total potential deal value $600m for 2 indications. A$39m
upfront, development and commercial milestones.
38
Comparables
NASH and C-Diff Market Cap ($US Millions as 03/06/16)
Leader in NASH; In PIII;
Positive Phase II funded by
NIH; Significant safety issues
(e.g., LDL); $6B+ valuation
increase with positive PII
$4,000
$3,600
- Average valuation for PII NASH
companies: $54M US (2.5X current
valuation)
- Average valuation for PIII NASH
companies: $2.1B (100X current
valuation)
- Average C-Diff Companies: $367M
Microbiome Leader; in PII in
C-Diff; Only open-label Phase
1/2 positive; very strong
institutional support
$3,500
$3,000
In PIII; Negative PII (placebo
response very high); Lost 500M
euro valuation on negative PII
$2,500
All NASH companies in PII:
- Tobira: Finishing PII
- Galectin: Cirrhotic patients
- Conatus: Cirrhotic patients
- Galmed: Just initiated PII;
Recruiting slowly
$2,000
$1,500
$1,000
$500
$1,160
$858
$208
$143
$105
$87
$0
NASH
$72
$40
C-Difficile
$62
$21
39
Immuron Limited
Investment Highlights
• Strong Platform – Product already launched; NIH sponsored trials; Support
from leading KOLs
• Strong Pipeline with Significant Upside – Two Phase II clinical trials with
differentiated profiles in multi-billion market (Fatty liver disease - NASH/ASH)
-
NASH: Phase II results - Mid-2017
ASH: Phase II results - 2018; 100% funded by NIH
C-difficile: Phase 1 results – Mid-2017
• Generating Growing Revenues from Marketed OTC Products – Targeting
WW $1.8M+ in 2016E; $3M-5M in 2017E; $30M/year peak revenues
• De-Risked Value Proposition – Significant upside from clinical assets,
coupled with growing revenues from OTC business
• Strong newsflow expected over the next 6-12 months
• Success in clinic could create licensing/M&A opportunity
40
APPENDICES
Extended Market Protection
Strong Patent Portfolio, Biologics Exclusivity and Gx Protection
Strong Patent
Portfolio
• 7 Major patent families offering both matter of
composition and formulation patents
• Approved / pending in major geographies including US,
Europe, Japan, China
• Earliest patent to 2026; possible extension to 2030
• Immuron’s drugs are considered “biologics” by the FDA
Extended
Market
Exclusivity
• In the US, this will confer Immuron’s new drugs 12 years of market
exclusivity, offering investors a long revenue tail
• Exclusively effectively extend time to potential first generic entry
• Immuron’s drug not absorbed in the blood
Generic
Protection
• No baseline for PK studies
• This results in lengthy process for Gx manufacturers with many
opportunities to challenge ANDA fillings
42
THANK YOU
Share your feedback
Discover